Alector, Inc. develops therapies for neurodegenerative diseases, focusing on improving brain health. The company advances a pipeline of therapeutic candidates that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Alector's approach combines insights from human genetics, neuroscience, and immunology to address critical challenges in the treatment of these conditions.
